Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Combination antibiotics effective against chlamydia-induced arthritis

29.04.2010
Findings of the multicenter NIH trial may be major step forward in managing this disease

Combination antibiotics effectively treat Chlamydia-induced reactive arthritis – a major step toward management, and possibly cure, of this disease, a federal multicenter clinical trial led by the University of South Florida College of Medicine found.

The trial, sponsored by the National Institute of Musculoskeletal and Skin Diseases, is reported in the May 2010 issue of Arthritis and Rheumatism, a journal of the American College of Rheumatology. The paper is accompanied by an editorial in which an internationally-recognized research group from Germany calls the study results "impressive."

"Our findings lend hope that eradication of this persistent infection is attainable and a possible cure exists," said John D. Carter, MD, associate professor of medicine in the USF Health Division of Rheumatology and lead author of the study.

Reactive arthritis (ReA), also known as Reiter's syndrome, is an autoimmune disorder that develops in response to an infection elsewhere in the body. This type of arthritis is most commonly caused by the bacteria Chlamydia trachomatis, usually acquired through sexual contact, or Chlamydia pneumoniae, which can trigger respiratory infection. The organism migrates from the initial site of infection – typically the genitourinary or respiratory tract – through the blood to the joint tissue. Pain and swelling in the sacroiliac joints, knees, ankles and feet are common.

Data suggests that the incidence of ReA rivals or even surpasses that of rheumatoid arthritis (an estimated 125,000 new cases a year), Dr. Carter said, but less is known about ReA, which is often misdiagnosed.

Most people recover fully from the initial flare-up of arthritis symptoms, but about 20 percent of those with ReA experience long-lasting symptoms. Studies have shown that the presence of metabolically-active Chlamydia in the joints of these individuals causes inflammation even years after the initial infection. That begged the question: could antibiotics treat Chlamydia-induced ReA? Previous clinical trials with single antibiotics were negative or failed to demonstrate any definitive effect.

A nine-month study by Dr. Carter and colleagues, published in 2004 in the Journal of Rheumatology, was the first to compare combination antibiotic therapy (doxycycline and rifampin) with monotherapy (doxycycline only). It showed a dramatic response to the combination in patients with Chlamydia-induced arthritis.

Based on these promising early results, the USF-led research team devised a new prolonged course of combination antibiotic treatment, which attacked two different pathways allowing Chlamydia infection to persist in the joints.

In the latest double-blind, placebo-controlled multicenter trial, 42 patients were randomly assigned to one of three treatment groups -- rifampin plus doxycycline, rifampin plus azithromycin, or placebo. All the patients tested positive for Chlamydia trachomatis or Chlamydia pneumoniae. They received combination antibiotics or placebo for six months and were followed for three months post-treatment.

Patients treated with the combination antibiotics improved significantly more in measures of the swelling and tenderness of joints and symptom assessment. In fact, the researchers report, 22 percent of patients receiving combination antibiotics experienced complete remission of ReA, while none in the placebo group did. Significantly more patients receiving combination antibiotics tested negative for Chlamydia bacteria in their blood or joint tissue following treatment. Adverse side effects, mostly gastrointestinal, were mild.

In an editorial appearing in the same issue as the USF-led study, Dr. Markus Rihl of Hannover Medical School in Germany writes, "the positive results using combination antibiotics are very promising to open a new way of treatment not only for Chlamydia-induced ReA but also for Chlamydia-induced spondylarthritis."

The editorial states the approach warrants further study to elucidate which antibiotic combination, dosing, and duration of therapy is most effective while minimizing the risk of bacterial resistance.

Other centers participating in the trial were Louisiana State Health Science Center, the University of Toronto and Wayne State University School of Medicine.

The study results were presented by Dr. Carter to 8,000 physicians and scientists at the annual meeting of American College of Rheumatology in the fall.

Article: "Combination Antibiotics as a Treatment for Chronic Chlamydia-Induced Reactive Arthritis." J. D. Carter, L. R. Espinoza, R. D. Inman, K. B. Sneed, L. R. Ricca, F. B. Vasey, J. Valeriano, J. A. Stanich, C. Oszust, H. C. Gerard, and A. P. Hudson. Arthritis & Rheumatism; Published Online: April 29, 2010; Print Issue Date: May 2010.

Editorial: "Combination Antibiotics for Chlamydia-Induced Arthritis: Breakthrough to a Cure?" Markus Rihl, Jens G. Kuipers, Lars Kohler, Henning Zeidler. Arthritis & Rheumatism; Published Online: April 29, 2010; Print Issue Date: May 2010.

USF Health

USF Health (www.health.usf.edu) is dedicated to creating a model of health care based on understanding the full spectrum of health. It includes the University of South Florida's colleges of medicine, nursing, and public health; the schools of biomedical sciences as well as physical therapy & rehabilitation sciences; and the USF Physicians Group. With more than $380.4 million in research grants and contracts last year, the University of South Florida is one of the nation's top 63 public research universities and one of only 25 public research universities nationwide with very high research activity that is designated as community-engaged by the Carnegie Foundation for the Advancement of Teaching.

Anne DeLotto Baier | EurekAlert!
Further information:
http://www.usf.edu

More articles from Life Sciences:

nachricht Are there sustainable solutions in dealing with dwindling phosphorus resources?
16.10.2017 | Leibniz-Institut für Nutzierbiologie (FBN)

nachricht Strange undertakings: ant queens bury dead to prevent disease
13.10.2017 | Institute of Science and Technology Austria

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Smart sensors for efficient processes

Material defects in end products can quickly result in failures in many areas of industry, and have a massive impact on the safe use of their products. This is why, in the field of quality assurance, intelligent, nondestructive sensor systems play a key role. They allow testing components and parts in a rapid and cost-efficient manner without destroying the actual product or changing its surface. Experts from the Fraunhofer IZFP in Saarbrücken will be presenting two exhibits at the Blechexpo in Stuttgart from 7–10 November 2017 that allow fast, reliable, and automated characterization of materials and detection of defects (Hall 5, Booth 5306).

When quality testing uses time-consuming destructive test methods, it can result in enormous costs due to damaging or destroying the products. And given that...

Im Focus: Cold molecules on collision course

Using a new cooling technique MPQ scientists succeed at observing collisions in a dense beam of cold and slow dipolar molecules.

How do chemical reactions proceed at extremely low temperatures? The answer requires the investigation of molecular samples that are cold, dense, and slow at...

Im Focus: Shrinking the proton again!

Scientists from the Max Planck Institute of Quantum Optics, using high precision laser spectroscopy of atomic hydrogen, confirm the surprisingly small value of the proton radius determined from muonic hydrogen.

It was one of the breakthroughs of the year 2010: Laser spectroscopy of muonic hydrogen resulted in a value for the proton charge radius that was significantly...

Im Focus: New nanomaterial can extract hydrogen fuel from seawater

Hybrid material converts more sunlight and can weather seawater's harsh conditions

It's possible to produce hydrogen to power fuel cells by extracting the gas from seawater, but the electricity required to do it makes the process costly. UCF...

Im Focus: Small collisions make big impact on Mercury's thin atmosphere

Mercury, our smallest planetary neighbor, has very little to call an atmosphere, but it does have a strange weather pattern: morning micro-meteor showers.

Recent modeling along with previously published results from NASA's MESSENGER spacecraft -- short for Mercury Surface, Space Environment, Geochemistry and...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

World Health Summit 2017: International experts set the course for the future of Global Health

10.10.2017 | Event News

Climate Engineering Conference 2017 Opens in Berlin

10.10.2017 | Event News

Conference Week RRR2017 on Renewable Resources from Wet and Rewetted Peatlands

28.09.2017 | Event News

 
Latest News

A single photon reveals quantum entanglement of 16 million atoms

16.10.2017 | Physics and Astronomy

The melting ice makes the sea around Greenland less saline

16.10.2017 | Earth Sciences

On the generation of solar spicules and Alfvenic waves

16.10.2017 | Physics and Astronomy

VideoLinks
B2B-VideoLinks
More VideoLinks >>>